Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Urologic Neoplasms 1Neoplasms 1Myasthenia Gravis 1Melanoma 1Limbic Encephalitis 1Hematologic Neoplasms 1Epilepsy 1Epilepsies, Partial 1Drug Resistant Epilepsy 1Colonic Neoplasms 1Autoimmune Diseases of the Nervous System 1Autoimmune Diseases 1

Interventions

Gemcitabine 6Trastuzumab 4Carboplatin 3pembrolizumab 2Pemetrexed 2Paclitaxel 2Cisplatin 2vinflunine 1tucatinib 1relatlimab 1palbociclib 1niraparib 1motexafin gadolinium 1montanide ISA 51 1flt3 ligand protein 1enfortumab vedotin 1cabozantinib 1atezolizumab 1apatorsen 1abemaciclib 1Zoledronic Acid 1Urinary Diversion 1Therapeutics 1Thalidomide 1Sunitinib 1Radiosurgery 1Nivolumab 1Mitomycin 1MART-1 Antigen 1Immunoglobulins, Intravenous 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Urologic Neoplasms × Immunoglobulins, Intravenous × Clear all
NCT00294476 2006-10-12

IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

GammaCan

Phase 2 Unknown
30 enrolled
DermatologicGastrointestinalGenitourinary

Colonic Neoplasms, Melanoma, Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡